Results of a post-hoc analysis underscore the efficacy of the Idiopathic Hypersomnia Severity Scale to measure symptoms of idiopathic hypersomia.
Research presented at Virtual SLEEP 2021 suggests the Idiopathic Hypersomnia Severity Scale (IHSS) is a reliable and comprehensive measure of excessive daytime sleepiness, sleep inertia, and self-reported global symptoms among individuals with idiopathic hypersomnia (IH).
“IH is a central hypersomnolence disorder characterized by excessive daytime sleepiness, prolonged nighttime sleep, and sleep inertia,” explained presenting author Yves Dauvilliers, MD, PhD, a professor at the Sleep and Wake Disorders Centre in the department of Neurology at Gui de Chauliac Hospital in France.
The IHSS, a 14-item, self-reported questionnaire, was designed to assess core IH symptom severity. “In a previous study we found that IHSS total scores were associated with the Epworth Sleepiness Scale (ESS) in patients with IH, untreated and treated subjects. However, the relationship between IHSS scores and other symptoms of IH measured with all the tools has not been formally established,” Dauvilliers said.
To address this knowledge gap, researchers conducted a post hoc analysis of data from a clinical trial (NCT03533114) evaluating lower-sodium oxybate (LXB, Xywav). IHSS efficacy served as a key secondary endpoint in the double-blind, placebo controlled randomized withdrawal period study.
Currently, LXB is approved for treatment of cataplexy and excessive daytime sleepiness among patients with narcolepsy in the United States.
At baseline, patients completed the IHSS and ESS, while the IHSS, ESS, and Patient Global Impression of Change (PGIc) were completed during an open label treatment titration and optimization period (OLTTOP). All 3 measures were also completed after the OLTTOP, after a stable-dose period (SDP), and after a double-blind, randomized withdrawal period (DBRWP). In addition, the sleep inertia visual analog scale (VAS-SI) was completed during screening, SDP, and DBRWP.
“This complex design was decided [on] to reduce the number of participants in it, which is important when studying a rare disease, and also to reduce the amount of time [patients are] taking the placebo,” Dauvilliers said.
Analyses revealed:
At least 10% of trial participants reported treatment emergent adverse events including nausea, headache, dizziness, anxiety and vomiting.
“In conclusion, in this study, LXB, low-sodium oxidate, demonstrated clinically meaningful effects on the ESS, PGIc, IHSS, and VAS-SI in participants with IH. The overall safety profile of LXB was consistent with what is known with sodium oxybate,” Dauvilliers said.
Reference
Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Correlation of the idiopathic hypersomnia severity scale with other measures of sleep parameters in a phase 3 trial. Presented at: Virtual SLEEP 2021; June 10-13, 2021; Virtual. Abstract 500.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More